DexCom Inc DXCM
Stock research in plain language · As of Oct 04, 2026 · updated once a week, after the trading week closes
What the company does
DexCom Inc is a large-cap company in the Healthcare sector (Medical Devices), with a market value of $32.2B, based in the USA.
It employs about 11,000 people and has been listed since Apr 14, 2005.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators.
Cheap or expensive? priced in line with its group
Its price-to-earnings (P/E) is 33.7 versus 31.6 for the median of the Healthcare sector in our universe (22 companies) — priced in line with its group.
Revenue is growing 13% versus the same quarter last year.
On analysts' next-year forecasts the multiple drops to 28.2 — they expect higher earnings.
The average analyst price target is 95.08, 11% above the current price (their view, not ours).
The stock sits at 81% of its one-year range (0% = the low, 100% = the high).
The risks
- No risk flags were detected from the data we have.
Strengths
- ✅ Profitable — 19 of every 100 dollars of revenue stays as profit.
- ✅ Generates free cash flow — profit becomes cash in the bank.
- ✅ Buys back its shares (4% fewer shares in a year).
- ✅ More cash than debt.
- ✅ Most analysts rate it buy (25 vs 0).
What changed this week
Over the past week the stock fell 1.4% (for comparison: S&P 500 -0.2%, sector ETF XLV -2.6%).
This week's news
- Why Medtronic’s $4 Billion MiniMed Exchange Offer Is Losing Its Allure finance.yahoo.com · 2026-10-02
- DXCM Report Highlights CGM Growth Opportunity in Type 2 Diabetes Care finance.yahoo.com · 2026-10-02
- Tandem Diabetes Care (TNDM) Is Up 7.2% After International Launch Of Mobi Insulin Pump System finance.yahoo.com · 2026-10-01
- Beta Bionics Stock Down Despite iLet-Eversense 365 Integration Deal finance.yahoo.com · 2026-09-29
- This Stock Could Be the Big Winner Out of Oura’s IPO finance.yahoo.com · 2026-09-28
- Tandem Mobi Automated Insulin Delivery System Now Available in Twelve International Markets finance.yahoo.com · 2026-09-28
A description of facts from the filings and the market — not investment advice or a recommendation. "Cheap" and "expensive" are always relative to the comparison group.